De la nécessité des études coût-efficacité en ostéoporose. [The necessity of cost-effectiveness analysis in osteoporosis]

Details

Serval ID
serval:BIB_01050A2EEDA3
Type
Article: article from journal or magazin.
Collection
Publications
Title
De la nécessité des études coût-efficacité en ostéoporose. [The necessity of cost-effectiveness analysis in osteoporosis]
Journal
Revue Médicale Suisse
Author(s)
Lamy O., Krieg M. A.
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
06/2007
Volume
3
Number
115
Pages
1521-5
Notes
English Abstract Journal Article --- Old month value: Jun 13
Abstract
Economic evaluations are increasingly being used by decision-makers to estimate the cost-effectiveness of interventions. Major changes have recently occurred in the treatment of osteoporosis. The development of a valid economic model (Markov) in the field of osteoporosis is discussed, as well as these limitations. Intervention, such hip protectors, calcium and vitamin D, bisphosphonates, hormonal replacement therapy, SERMs, strontium ranelate, analogue of parathyroid hormone are analysed in the light of cost-effectiveness analyses.
Keywords
Aged Aged, 80 and over Bone Density Conservation Agents/economics/therapeutic use Calcium/economics/therapeutic use Cost-Benefit Analysis Decision Making Diphosphonates/economics/therapeutic use Female Fractures, Bone/economics/prevention & control Health Care Costs Hip Fractures/economics/prevention & control Hormone Replacement Therapy/economics Humans Male Markov Chains Middle Aged Models, Economic Organometallic Compounds/economics/therapeutic use Osteoporosis/drug therapy/*economics Parathyroid Hormone/analogs & derivatives/economics Quality of Life Selective Estrogen Receptor Modulators/economics/therapeutic use Thiophenes/economics/therapeutic use Vitamin D/economics/therapeutic use
Pubmed
Create date
25/01/2008 14:55
Last modification date
03/03/2018 13:13
Usage data